PeerVoice Endocrinology & Metabolic Disorders Audio

Epizode

• 
  Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health 29.06.2026 1h 17min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/VAC860. Presented by Carel le Roux, MBChB, MSc, PhD; Biykem Bozkurt, MD, PhD; Domenica M. Rubino, MD; and Michael Donnelly-Boylen, MS. Learning Objectives: Describe the pathophysiologic relationship between obesity, metabolic dysfunction, and end-organ injury across cardiovascular, renal, and metabolic disease; Evaluate key clinical and psychosocial factors that influence multidisciplinary management decisions for patients with obesity and related cardiovascular-renal-metabolic disease; Apply evidence-based strategies to initiate and coordinate holistic, long-term weight management plans integrating nutrition, physical activity, behavioral, and pharmacologic interventions; Interpret the evolving rationale and design of emerging therapeutic approaches that target obesity as a root cause of multi-organ disease.
• 
  Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease 09.06.2026 25min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/YWG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Cyrielle Caussy, MD, PhD. Learning Objectives: Recognise the bidirectional relationship between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), including the impact of MASH on glycaemic control, insulin resistance, and complications; Explain the rationale for prompt identification and active management of individuals with MASH and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel liver-directed therapies, such as thyroid hormone receptor beta (THR-β) agonists, on the underlying pathophysiology and progression of the disease, including in individuals receiving treatment for T2D; List appropriate non-invasive tests for determining the presence of liver steatosis and fibrosis in endocrinology patients at increased risk for MASH.
• 
  Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice 18.05.2026 35min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/FAK860. Presented by Sven Francque, MD, PhD; and José Luis Calleja Panero, MD, PhD. Learning Objectives: Recall the rationale for prompt identification of metabolic dysfunction-associated steatohepatitis (MASH) in gastroenterology patients, including the high prevalence in specific patient groups, the risk of progression, and the availability of novel treatments; Use recommended non-invasive blood- and image-based methods to evaluate for evidence of steatosis and fibrosis among individuals with cardiometabolic risk factors; Identify individuals with MASH and fibrosis who are appropriate candidates for timely initiation of disease-specific treatment or who may benefit from referral to a specialist in liver fibrosis.
• 
  Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes 29.04.2026 1h 19min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/ACQ860. Presented by Colin M. Dayan, MA, MBBS, FRCP, PhD; Michael J. Haller, MD; and Olga Kordonouri, MD. Learning Objectives: Explain the clinical rationale and existing evidence for use of immunomodulatory therapies to delay the progression of type 1 diabetes (T1D); Identify practical workflows and protocols that facilitate the potential integration of immunomodulatory infusions into endocrinology practice, including care pathways for T1D; Evaluate patient perspectives and considerations related to the receipt of immunomodulatory infusions for T1D.
• 
  Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can 29.04.2026 20min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Identify proactive and systematic approaches that can be practically implemented in gastroenterology practices for the assessment of fibrosis risk in individuals with specific characteristics and comorbid conditions.
• 
  Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies 04.02.2026 21min

  For the complete activity, including supporting material, please visit https://www.peervoice.com/XZR860. Presented by Melanie J. Davies, CBE, MBChB, MD, FMedSci and Linong Ji, MD. Learning Objectives: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal complications in patients with T2DM; Propose practical approaches to address cost and clinical effectiveness for patients with T2DM.
• 
  Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management 14.01.2026 29min

  Visit https://www.peervoice.com/URW860 to view the entire programme with slides. After completing “Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management”, participants will be able to: Identify patients with persistent chylomicronemia, including familial chylomicronemia syndrome (FCS), based on clinical presentation and recommended diagnostic criteria; Recall the mechanisms of and evidence for novel treatments for management of FCS; and Apply comprehensive, patient-centered approaches to the management of persistent chylomicronemia, including FCS.
• 
  Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities 31.12.2025 9min

  Visit https://www.peervoice.com/NNA860 to view the entire programme with slides. After completing “Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities”, participants will be able to: Evaluate the impact of APOC-III—directed therapies on clinical and patient-centered outcomes in familial chylomicronemia syndrome (FCS); and Differentiate between APOC-III—directed therapies approved for the management of FCS, including their molecular modalities, frequency of administration, contraindications to use, and adverse-event profiles.
• 
  John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes 23.12.2025 30min

  Visit https://www.peervoice.com/FTR860 to view the entire programme with slides. After completing “John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes”, participants will be able to: Summarize the complications, burden, and unmet needs associated with the diagnosis and management of hypercortisolism; Describe the mechanistic rationale associated with new and emerging therapies in hypercortisolism; Recall safety and efficacy data relating to new and emerging treatment strategies in patients with hypercortisolism; and Appraise recent data regarding newer therapies in the context of current approaches to the management of difficult-to-treat metabolic disease.
• 
  Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists 19.11.2025 32min

  Visit https://www.peervoice.com/AEX860 to view the entire programme with slides. After completing “Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists”, participants will be able to: Describe key efficacy and safety outcomes observed with use of PPAR agonists in specific subgroups of people with primary biliary cholangitis (PBC), including those with previous exposure to fibrates or obeticholic acid and those with compensated cirrhosis; Evaluate rates of biochemical response and alkaline phosphatase normalisation observed with novel PPAR agonists in individuals with PBC; and Assess the impact of novel PPAR agonists on pruritus and quality-of-life measures in individuals with PBC.
• 
  David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach? 08.11.2025 41min

  Visit https://www.peervoice.com/RNT860 to view the entire programme with slides. After completing “David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?”, participants will be able to: Describe the contemporary approach to pharmacologic treatment of primary biliary cholangitis (PBC); Identify individuals with PBC who may benefit from initiation of second-line treatment options or a transition in second-line treatment approach; and Apply available data to guide the personalisation of second-line treatment choice for individuals with PBC based on person- and disease-specific characteristics (eg, presence of moderate-to-severe pruritus or compensated cirrhosis, prior treatment with fibrates or obeticholic acid [OCA]).
• 
  Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room 11.09.2025 18min

  Visit https://www.peervoice.com/NUF860 to view the entire programme with slides. After completing “Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room”, participants will be able to: Discuss the impact of delayed and/or misdiagnosis of a rare cause of abdominal pain on patients and healthcare systems; Recognise the clinical features that would increase suspicion of a rare cause of abdominal pain; and Apply appropriate diagnostic algorithms for patients who present to the emergency room with severe abdominal pain and in whom the findings from a typical work-up are inconclusive.
• 
  Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence 27.08.2025 9min

  Visit https://www.peervoice.com/STJ860 to view the entire programme with slides. After completing “Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence”, participants will be able to: Improved knowledge of current efficacy data from clinical trials of novel treatments for familial chylomicronemia syndrome (FCS); and Improved knowledge of the safety profiles of emerging treatments for FCS, based on clinical trial outcomes.
• 
  Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment 20.08.2025 19min

  Visit https://www.peervoice.com/EAW860 to view the entire programme with slides. After completing “Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment”, participants will be able to: Recognise unmet needs and burdens experienced by patients living with inadequately controlled chronic spontaneous urticaria (CSU); Provide appropriate, individualised treatment to patients with CSU whose symptoms are inadequately controlled with second-generation H1-antihistamines; and Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatment approaches (such as BTK inhibitors) in the management of CSU.
• 
  Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice 04.08.2025 30min

  Visit https://www.peervoice.com/UYE860 to view the entire programme with slides. After completing “Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice”, participants will be able to: Describe the key components involved in maintaining food intake homeostasis and how these influence appetite and eating behaviour in obesity; Appraise the evidence surrounding phenotype-guided approaches to obesity management; Implement practical, culturally competent strategies to overcome barriers to optimal obesity care and address unmet needs amongst patients in the Black community; and Utilise practical approaches that consider obesity phenotype and concomitant diseases, including depression, to establish sustainable individualised treatment strategies in the management of obesity.
• 
  Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis 23.06.2025 18min

  Visit https://www.peervoice.com/BAN860 to view the entire programme with slides. After completing “Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis”, participants will be able to: Explain the mechanistic rationale for OX40 pathway inhibitors in atopic dermatitis (AD); Describe the benefits and limitations of current disease management strategies in AD; and Use clinical data to evaluate the effects of emerging OX40 inhibitors for patients with AD in the context of current clinical management.
• 
  Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges 30.05.2025 19min

  Visit https://www.peervoice.com/HAR860 to view the entire programme with slides. After completing “Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges”, participants will be able to: Evaluate epidemiological evidence on the incidence of misclassification of type 1 diabetes in adults as type 2 diabetes; Recognise differential diagnoses of type 1 diabetes in adults; and Identify patients who are receiving treatment for type 2 diabetes who have clinical features of type 1 diabetes and should undergo further diagnostic testing.
• 
  Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa 08.04.2025 28min

  Visit https://www.peervoice.com/CCB860 to view the entire programme with slides. After completing “Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa”, participants will be able to: Recognise barriers to optimal care faced by patients with hidradenitis suppurativa (HS), including delays in diagnosis and therapeutic area; Recall the results of clinical trials and real-world studies assessing short- and long-term outcomes associated with the use of biologic therapies in the management of HS; and Formulate appropriate, individualised treatment plans for patients with HS based on their goals of therapy, type and severity of HS, and present comorbidities.
• 
  Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis 17.02.2025 28min

  Visit https://www.peervoice.com/WWZ860 to view the entire programme with slides. After completing “Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis”, participants will be able to: Outline the role of patient perspectives of disease burden in making shared decisions about treatment selection in primary biliary cholangitis (PBC); Summarize the clinical data pertaining to current and emerging first- and second-line therapies used in the management of patients with PBC; Utilize guideline recommendations for evaluation of symptoms and response to therapy in patients with PBC; and Use individualized evidence-based treatment strategies that incorporate the perspectives of patients with PBC.
• 
  Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations 30.12.2024 20min

  Visit https://www.peervoice.com/EBC860 to view the entire programme with slides. After completing “Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations”, participants will be able to: Explain the rationale for timely diagnosis and optimised treatment of people living with primary biliary cholangitis (PBC); Recognise current gaps in the identification and treatment of PBC, including differences based on factors such as gender, race, age, and geography; and Apply evidence-based approaches to the diagnosis and management of PBC to address unmet needs across diverse patient population.